77,409 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Bought by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. purchased a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 77,409 shares of the company’s stock, valued at approximately $4,332,000.

Other hedge funds have also recently modified their holdings of the company. UMB Bank n.a. lifted its holdings in 10x Genomics by 51.6% in the fourth quarter. UMB Bank n.a. now owns 782 shares of the company’s stock valued at $44,000 after acquiring an additional 266 shares during the period. Harvest Fund Management Co. Ltd acquired a new stake in 10x Genomics in the fourth quarter valued at $66,000. Van ECK Associates Corp lifted its holdings in 10x Genomics by 23.4% in the fourth quarter. Van ECK Associates Corp now owns 1,908 shares of the company’s stock valued at $107,000 after acquiring an additional 362 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in 10x Genomics in the third quarter valued at $146,000. Finally, Powell Investment Advisors LLC acquired a new stake in 10x Genomics in the fourth quarter valued at $200,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TXG has been the subject of several research reports. Stifel Nicolaus cut their price target on 10x Genomics from $63.00 to $53.00 and set a “buy” rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft cut their price target on 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. The Goldman Sachs Group cut their price target on 10x Genomics from $30.00 to $26.00 and set a “sell” rating for the company in a research note on Wednesday. UBS Group cut their price target on 10x Genomics from $52.00 to $30.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, Canaccord Genuity Group cut their price target on 10x Genomics from $65.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, April 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

10x Genomics Trading Up 4.5 %

TXG traded up $1.19 during midday trading on Friday, hitting $27.48. The company’s stock had a trading volume of 2,385,262 shares, compared to its average volume of 1,968,632. The firm has a market cap of $3.27 billion, a P/E ratio of -12.32 and a beta of 1.94. The firm has a 50-day moving average price of $35.81 and a two-hundred day moving average price of $42.10. 10x Genomics, Inc. has a 52-week low of $24.60 and a 52-week high of $63.57.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Tuesday, April 30th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). The company had revenue of $141.01 million during the quarter, compared to analysts’ expectations of $142.24 million. 10x Genomics had a negative return on equity of 30.85% and a negative net margin of 42.20%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.44) EPS. On average, equities analysts expect that 10x Genomics, Inc. will post -1.56 EPS for the current year.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 4,660 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $44.00, for a total value of $205,040.00. Following the transaction, the chief executive officer now directly owns 842,900 shares of the company’s stock, valued at approximately $37,087,600. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Justin J. Mcanear sold 1,865 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $86,424.10. Following the completion of the sale, the chief financial officer now directly owns 95,240 shares in the company, valued at approximately $4,413,421.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Serge Saxonov sold 4,660 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $44.00, for a total value of $205,040.00. Following the completion of the sale, the chief executive officer now owns 842,900 shares of the company’s stock, valued at $37,087,600. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,959 shares of company stock valued at $592,806. Corporate insiders own 10.65% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.